Table 3.
Drug/vehicle | Concentration (μM) | Arterial pressure (mmHg) (mean±s.e.m.) | n | P | % Change | |
---|---|---|---|---|---|---|
Control | Treated | |||||
DMSO | 0.05% | 54.25±6.29 | 51.17±9.60 | 6 | >0.05 | 2.07 |
L-NAME | 100 | 51.00±15.64 | 53.25±15.43 | 10 | >0.05 | 4.41 |
L-NAME | 10 | 58.33±6.03 | 61.44±5.70 | 4 | >0.05 | 5.33 |
L-Arginine | 1000 | 64.60±13.98 | 67.20±15.77 | 5 | >0.05 | 4.02 |
D-Arginine | 1000 | 46.33±0.95 | 45.00±1.58 | 6 | >0.05 | 2.88 |
L-Arg+L-NAME | 1000 +100 | 56.50±9.33 | 58.83±9.20 | 6 | >0.05 | 4.13 |
Sodium azide (AZ) | 10 | 62.60±11.88 | 62.00±9.94 | 5 | >0.05 | 0.96 |
AZ | 1 | 48.67±10.14 | 50.33±8.85 | 6 | >0.05 | 3.43 |
AZ | 0.1 | 47.80±14.22 | 47.40±11.97 | 5 | >0.05 | 0.84 |
AZ+ODQ | 10+10 | 52.17±12.88 | 53.00±12.76 | 6 | >0.05 | 1.60 |
SNP | 100 | 53.53±7.14 | 52.00±6.16 | 7 | >0.05 | 2.93 |
SNP | 10 | 46.43±11.96 | 45.57±11.82 | 7 | >0.05 | 1.85 |
SNP | 1 | 48.50±7.24 | 51.00±7.38 | 6 | >0.05 | 5.15 |
SNP+ODQ | 100 +10 | 49.00±7.97 | 49.20±8.78 | 5 | >0.05 | 0.41 |
8-pCPT-cGMP | 10 | 48.67±7.15 | 49.00±8.19 | 6 | >0.05 | 0.68 |
8-pCPT+ODQ | 10+10 | 60.75±12.88 | 59.25±13.11 | 6 | >0.05 | 2.47 |
ODQ | 10 | 60.75±13.1 | 59.00±12.39 | 4 | >0.05 | 2.90 |
The arterial pressure was recorded in mmHg and was shown as mean±s.e.m. The control arterial pressures represent the average arterial pressure of the eyes of each treatment group before addition of drug. The treated arterial pressures represent the average arterial pressure of the respective eyes at the end of 60 min of drug treatment. Note that for each group of eyes, arterial pressure recorded during the first 30 min prior to drug addition was taken as the control values. Pressure recorded for the subsequent 40–60 min after establishment of drug effects was taken as treated values.